Fundraising FoxGenoa Pharmaceuticals
San Diego, US · Founded 2011 · Delaware corporation · 4 known investors
Find your way into Genoa Pharmaceuticals
Sign up to see every warm intro you have to Genoa Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Genoa Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Its lead asset is inhaled pirfenidone (Aerodone), a nebulized reformulation designed to deliver effective lung levels while reducing the side effects of oral dosing.
Founders & leadership
Genoa Pharmaceuticals was founded in 2011 by Mark W. Surber, Ph.D..
MW
Mark W. Surber, Ph.D.Founder
RG
Richard G. VincentExecutive
Board
MJ
Michael J. KamdarBoard director
DD
Daniel D. BurgessBoard director
Investors · 4
F-Prime CapitalreportedCambridge · $3M – $10M
How we know: funding news · Not right? Tell us
Norwest Venture PartnersinferredMenlo Park · $10M – $30Mvia Tiba Aynechi · board
How we know: board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$245.1M disclosed across 4 rounds · 2011–2023
▶$189.2MraisedOct 2023 · 26 investors · BiotechnologyRule 506(b)
▶$189.2MraisedOct 2023 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lyn BaranowskiExecutive Officer, Director
- Tiba AynechiDirector
- Ketan PatelDirector
- Peter MoldtDirector
- Niall O'DonnellDirector
- Cassandra Gianna LucaDirector
- Jonathan LeffDirector
- Jill CarrollDirector
- Offering amount
- $189.2M
- Amount sold
- $189.2M
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35.5MraisedMay 2020 · 8 investors · BiotechnologyRule 506(b)
▶$35.5MraisedMay 2020 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Niall O'DonnellDirector
- Jonathan LeffDirector
- Sofia IoannidouDirector
- Tiba AynechiDirector
- Heather PrestonDirector
- Ketan PatelDirector
- A. Bruce MontgomeryExecutive Officer, Director
- Robert MittendorffDirector
- Offering amount
- $35.7M
- Amount sold
- $35.5M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.2MraisedMay 2017 · 46 investors · PharmaceuticalsRule 506(b)
▶$18.2MraisedMay 2017 · 46 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan Leff, M.D.Director
- Bruce Montgomery, M.D.Director, Executive Officer
- Ketan PatelDirector
- Naveed SiddiqiDirector
- Heather PrestonDirector
- Niall O'DonnellDirector
- Mark W. Surber, Ph.D.Executive Officer
- Tiba AynechiDirector
- Offering amount
- $64.9M
- Amount sold
- $18.2M
- Minimum investment
- $1
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedAug 2015 · 41 investors · PharmaceuticalsRule 506(b)
▶$2.2MraisedAug 2015 · 41 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. KamdarDirector
- Daniel D. BurgessDirector
- Richard G. VincentExecutive Officer
- Mark W. Surber, Ph.D.Executive Officer, Director
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Minimum investment
- $1
- First sale
- Oct 2011
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Avalyn Pharma IncAvalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies. The company operates in the biotech and respiratory drug development space.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
F-Prime CapitalBeam Therapeutics develops CRISPR base editing technology to create precision genetic medicines for treating human diseases. The company focuses on therapeutic applications using single-letter DNA modifications.
Companies working in the same space as Genoa Pharmaceuticals.
Frequently asked questions
- What does Genoa Pharmaceuticals do?
- Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Its lead asset is inhaled pirfenidone (Aerodone), a nebulized reformulation designed to deliver effective lung levels while reducing the side effects of oral dosing.
- Who founded Genoa Pharmaceuticals?
- Genoa Pharmaceuticals was founded by Mark W. Surber, Ph.D. in 2011.
- Who are Genoa Pharmaceuticals's investors?
- Genoa Pharmaceuticals's investors include F-Prime Capital, Norwest Venture Partners, RiverVest Venture Partners, Sofinnova Ventures.
- How much funding has Genoa Pharmaceuticals raised?
- Genoa Pharmaceuticals has disclosed $245.1M raised across 4 rounds.
- Where is Genoa Pharmaceuticals headquartered?
- Genoa Pharmaceuticals is headquartered in San Diego, US.